Xspray Pharma: Dasynoc CRL – our comments - Redeye

The scenario we outlined in our Q2 update has largely materialised, with Xspray reporting a Dasynoc CRL as the CDMO remains uncleared and the FDA requested additional batch data. This likely takes a 2026 launch off the table while elevating the dilution risk ahead of a potential approval.

Länk till analysen i sin helhet: https://www.redeye.se/research/1179940/xspray-pharma-dasynoc-crl-our-comments?utm_source=finwire&utm_medium=RSS